Home › Small Cell Lung Cancer › Tennessee
Small Cell Lung Cancer clinical trials in Tennessee
24 studies for Small Cell Lung Cancer are looking for participants at sites in Tennessee.
Cities in Tennessee
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT03460977A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Baptist Cancer Center - Memphis, Memphis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07472517DESTINY-PANTUMOUR04
- Research Site, Nashville
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 280619, Knoxville
- University Of Tennessee Medical Center /ID# 279896, Knoxville
- Baptist Memorial Hospital /ID# 281405, Memphis
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Sarah Cannon - Tennessee Oncology, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07325136A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- SCRI OP (Oncology Partners), Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- SCRI Oncology Partners, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06646276A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
- Sarah Cannon Research Institute ( Site 7001), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06780137Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- West Cancer Center & Research Institute, Germantown
- University of Tennessee Medical Center, Knoxville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 to 100 · All sexes · Updated Aug 27, 2026 · NCT06726148A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
- Sarah Cannon Research Institute (SCRI), Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07488923Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Baptist Cancer Center, Memphis
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Aug 21, 2026 · NCT07531095A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- SCRI Oncology Partners, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- THE WEST CLINIC, PLLC dba West Cancer Center, Germantown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06203210Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
- Tennessee Oncology, PLLC, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06931626A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06131840A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Sarah Cannon Research Institute - Oncology Partners, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583A Study of LY4175408 in Participants With Advanced Cancer
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 136, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.